Since its launch, the FAILSAFE initiative has rapidly become a central driver of innovation in tackling the global challenge of fungal antimicrobial resistance (fAMR). Across its first two rounds of funding, FAILSAFE has supported 28 impactful projects led by researchers from 94 institutions spanning 31 countries worldwide.
With nearly £2.87 million invested, these projects range from early-stage seedcorn grants to larger-scale investigations, designed to fast-track solutions that address the disproportionate burden of fungal diseases in low- and middle-income countries (LMICs).
This broad, collaborative portfolio underpins advances across five crucial areas: understanding antifungal resistance, developing next-generation antifungals, enriching pathogen surveillance, pioneering vaccine research, and innovating diagnostics.
The diverse network of internationally-renowned institutions and researchers illustrates the program’s strength—not only funding cutting-edge science but also building a truly global community united in combatting an urgent and overlooked health crisis.
Further rounds of funding are planned and will be advertised on this website. Check back soon for updates!
For more details sign up to the CMM-FAILSAFE Medical Mycology network https://cmm-failsafe.com/become-a-member/
